Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
Luckily for you, we at StockStory have no conflicts of interest - our sole job is to help you find genuinely promising companies. That said, here are three stocks where Wall Street may be overlooking some important risks and some alternatives with better fundamentals.
Shake Shack (SHAK)
Consensus Price Target: $113.40 (25% implied return)
Started as a hot dog cart in New York City's Madison Square Park, Shake Shack (NYSE: SHAK) is a fast-food restaurant known for its burgers and milkshakes.
Why Does SHAK Fall Short?
- Subpar operating margin of 2.4% constrains its ability to invest in process improvements or effectively respond to new competitive threats
- Underwhelming 0.1% return on capital reflects management’s difficulties in finding profitable growth opportunities
Shake Shack is trading at $90.69 per share, or 64.7x forward P/E. If you’re considering SHAK for your portfolio, see our FREE research report to learn more.
Medifast (MED)
Consensus Price Target: $12 (18.9% implied return)
Known for its Optavia program that combines portion-controlled meal replacements with coaching, Medifast (NYSE: MED) has a broad product portfolio of bars, snacks, drinks, and desserts for those looking to lose weight or consume healthier foods.
Why Do We Steer Clear of MED?
- Annual sales declines of 37.7% for the past three years show its products struggled to connect with the market
- Revenue base of $385.8 million puts it at a disadvantage compared to larger competitors exhibiting economies of scale
- Falling earnings per share over the last three years has some investors worried as stock prices ultimately follow EPS over the long term
Medifast’s stock price of $10.10 implies a valuation ratio of 9.9x forward EV-to-EBITDA. Dive into our free research report to see why there are better opportunities than MED.
Assurant (AIZ)
Consensus Price Target: $261.33 (19.3% implied return)
With roots dating back to 1892 when it was founded by a Civil War veteran, Assurant (NYSE: AIZ) provides specialized insurance products and services that protect major consumer purchases like mobile devices, vehicles, homes, and appliances.
Why Do We Think Twice About AIZ?
- Outsized scale creates growth headwinds as its 4.8% annualized net premiums earned increases over the last five years underperformed other financial institutions
- Earnings growth over the last two years fell short of the peer group average as its EPS only increased by 13.1% annually
- Sizable asset base leads to capital growth challenges as its 2.8% annual book value per share increases over the last five years fell short of other insurance companies
At $218.99 per share, Assurant trades at 1.7x forward P/B. Check out our free in-depth research report to learn more about why AIZ doesn’t pass our bar.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
